Pharmfactor, a member of the corporate group lead by Biomedycyna Polska S. A., significantly accelerates development thanks to over 2 million zł grant for research involved in biotechnological project, in which the company’s science team develops effective technologies for obtaining hyaluronidase of high activity.

Pharmfactor focuses on designing breakthrough technological solutions, which will satisfy the needs of the national and global biotechnological market. Company’s activity in the field of production of specialized biopharmaceutical products is founded on many years of experience, which establishes Pharmfactor as a trusted business partner and an initiator of incoming changes in the pharmaceutical sector.

Funding in the form of a 2 million zł grant for research and development is an opportunity for establishing a strategic advantage and introduction of a product, which quality significantly exceeds other preparations of similar type already present on the market. The end product is a highly active enzyme, purified using improved technological process.

Project consists of two phases:  industrial research and experimental development, with the goal of producing hyaluronidase of high specific activity. Efforts are also made to increase the scale of the technological process from laboratory to semi-preparative, while simultaneously implementing efficient and economical technologies for isolation and purification of the protein.

Project “Development of technology for obtaining highly active hyaluronidase” is co-financed by European Union, project number: RPDS.01.02.01-02-0149/17.